Phraxis

About Phraxis

Phraxis Inc. is a Minneapolis-based medical device company that also operates under the name Cardio Flow, focusing on separate vascular intervention technologies. Phraxis was founded in 2008 by John Seaberg and is led by CEO Dr. Alexander Yevzlin. The company has raised a total of $14.4 million over six funding rounds.

Under the Phraxis brand, the company develops solutions for vascular access in hemodialysis patients. Its lead product, the EndoForce™ Connector, received FDA approval in May 2025. The EndoForce™ is a patented endovascular implant designed to simplify the creation of arteriovenous grafts (AVGs) for hemodialysis. This transcatheter-delivered device enables an endovascular anastomosis, which connects the graft to the patient's vein without requiring traditional open surgical dissection. Key features include anchoring barbs for secure placement and a flexible ePTFE-covered nitinol segment that conforms to the vessel wall, promoting better blood flow. In clinical trials, the EndoForce™ demonstrated a 92% cumulative patency rate at six months, an improvement over the typical 80% rate for standard sutured techniques. The device is intended to reduce tissue trauma, streamline the procedure, and improve the long-term performance of dialysis access grafts for patients with end-stage renal disease (ESRD).

Through its Cardio Flow division, the company develops and markets the FreedomFlow® Orbital Atherectomy System for treating peripheral artery disease (PAD). This platform, which received FDA 510(k) clearance in October 2023, is a catheter-based device used to remove atherosclerotic plaque from arteries in the legs. The system's design leverages angular momentum with five diamond-coated spheres that maintain simultaneous contact with the vessel wall, allowing for efficient plaque removal. It is designed for versatility, capable of treating vessels from 2 mm to 8 mm in diameter, and does not require capital equipment, offering potential cost savings for hospitals and clinics.